van Houte Hans 4
4 · Nurix Therapeutics, Inc. · Filed Jan 30, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) CFO Hans van Houte Exercises RSUs and Sells Shares
What Happened
- Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), had restricted stock units (RSUs) convert/exercise into shares (derivative code M) totaling 11,496 shares on 2026-01-30 at $0.00 per share. On the same date he sold 3,661 shares in open-market transactions for aggregate proceeds of approximately $60,766.
- The sales were routine "sell-to-cover" transactions to satisfy tax withholding obligations associated with the RSU vesting; they are not described as discretionary open-market trades by the reporting person.
Key Details
- Transaction date: 2026-01-30.
- RSU/derivative conversions: 2,887 + 2,000 + 3,750 + 2,859 = 11,496 shares acquired (exercise/convert at $0.00).
- Open-market sales: 3,588 shares at a weighted avg $16.58 (total ~$59,498; price range $16.33–$17.32) and 73 shares at a weighted avg $17.37 (total ~$1,268; price range $17.33–$17.49). Total proceeds ≈ $60,766.
- Notable footnotes: F1 — sales were mandated sell-to-cover for tax withholding; F4–F9 — RSUs represent contingent rights to common stock with specified vesting schedules. F2/F3 provide sale price ranges and weighted averages.
- Filing timeliness: Reported on 2026-01-30 for the same transaction date — no late filing indicated in the provided data.
- Shares owned after the transaction: Not specified in the excerpt provided.
Context
- The M code indicates conversion/exercise of derivatives (here, RSUs converting to common stock). Because some or all of the newly issued shares were sold to cover taxes (sell-to-cover), this is a routine tax-related transaction rather than an independent investment decision. Such sell-to-cover trades are common after RSU vesting and do not necessarily signal insider sentiment about the stock.
Insider Transaction Report
Form 4
van Houte Hans
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-30+2,887→ 40,479 total - Exercise/Conversion
Common Stock
2026-01-30+2,000→ 42,479 total - Exercise/Conversion
Common Stock
2026-01-30+3,750→ 46,229 total - Exercise/Conversion
Common Stock
2026-01-30+2,859→ 49,088 total - Sale
Common Stock
[F1][F2]2026-01-30$16.58/sh−3,588$59,498→ 45,500 total - Sale
Common Stock
[F1][F3]2026-01-30$17.37/sh−73$1,268→ 45,427 total - Exercise/Conversion
Restricted Stock Units
[F4][F5][F6]2026-01-30−2,887→ 0 totalExercise: $0.00→ Common Stock (2,887 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F7][F6]2026-01-30−2,000→ 2,000 totalExercise: $0.00→ Common Stock (2,000 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F8][F6]2026-01-30−3,750→ 18,750 totalExercise: $0.00→ Common Stock (3,750 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F9][F6]2026-01-30−2,859→ 25,725 totalExercise: $0.00→ Common Stock (2,859 underlying)
Footnotes (9)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F4]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F5]The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- [F6]RSUs do not expire; they either vest or are canceled prior to the vest date.
- [F7]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F8]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F9]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte|2026-01-30